<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02418065</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0231</org_study_id>
    <nct_id>NCT02418065</nct_id>
  </id_info>
  <brief_title>Multimodal Therapeutic Approach in Undernourished Maintenance Hemodialysis Patients (AMERICANO)</brief_title>
  <acronym>AMERICANO</acronym>
  <official_title>Multimodal Therapeutic Approach by Exercise, Oral Nutritional Supplementation, Omega 3 and Androgen in Undernourished Maintenance Hemodialysis Patients (AMERICANO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Nutrition Research Center Rhône-Alpes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société Francophone Nutrition Clinique et Métabolisme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NUTRICIA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate a 3 months integrated multimodal therapeutic approach
      including exercise training program with ergocycle during dialysis sessions, oral nutritional
      supplementation, omega 3 and androgen, on effort tolerance and quality of life of
      under-nourish maintenance hemodialysis Chronic Kidney Disease (CKD) patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate a 3 months integrated multimodal therapeutic approach
      including exercise training program with ergocycle during dialysis sessions, oral nutritional
      supplementation, omega 3 and androgen, on effort tolerance and quality of life of
      under-nourish maintenance hemodialysis Chronic Kidney Disease (CKD) patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of physical endurance on bicycle</measure>
    <time_frame>At months 3 and 15 after inclusion</time_frame>
    <description>Physical endurance on bicycle at intermediate power between maximal power and ventilatory threshold power (Pmax+Pthreshold)/2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transthyrin serum concentration evolution</measure>
    <time_frame>at day 1</time_frame>
    <description>(Unit of Measure: g/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life assessment using SF-36 scale and KDQOL</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky score</measure>
    <time_frame>at ady 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal power on bicycle</measure>
    <time_frame>at day 1</time_frame>
    <description>Unit of Measure: Watt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional parameters</measure>
    <time_frame>at day 1</time_frame>
    <description>weight (Kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum levels of albumin (g/L)</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determination of urea (mmol/L)</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determination of creatinine(µmol/L)</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>at day 1</time_frame>
    <description>(evaluated by bioimpedance)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Kidney Failure</condition>
  <arm_group>
    <arm_group_label>treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>testosteron, oral nutritional supplementation, n3 polyunsaturated fatty acid, training on ergonomic bicycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>oral nutritional supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>training on ergonomic bicycle</intervention_name>
    <arm_group_label>treated group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <arm_group_label>treated group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral nutritional supplementation</intervention_name>
    <arm_group_label>treated group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>n3 polyunsaturated fatty acid</intervention_name>
    <arm_group_label>treated group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemodialysis patient since at least 6 month

          -  Patient aged 18 years or older

          -  Written consent to participate in the study

          -  No acute infection or hospitalization

          -  Opinion of Cardiologist saying there is no known evidence against the evaluation of
             the maximum exercise capacity

          -  Protein-energy wasting diagnosed if at least two of this characteristics are present

          -  Serum albumin &lt;3.8 g per 100 ml (Bromcresol Green)

          -  Serum prealbumin (transthyretin) &lt;30mg per 100 ml

          -  Reduce body mass (BMI &lt;23)

          -  Unintentional 10% weight loss over 6 months

          -  Lean body mass index &lt; 10th percentile

        Exclusion Criteria:

          -  Presence of comorbidity which compromising the survival within 6 month

          -  Unintentional low DEI &lt;20 kcal kg_1 day_1

          -  HIV or HCV positive

          -  History of hormone dependent cancer

          -  Suspected or confirmed prostate cancer or breast carcinoma

          -  Known hypersensitivity for testosterone

          -  Presence or history of hepatic tumor

          -  Inability to follow the rehabilitation program

          -  Inadequate dialysis dosage (&lt;12 hours / week or Kt/V index&lt; 1,2) Pregnant or planning
             pregnancy and lactating women during study period

          -  Adult patient protected by law

          -  Patient who don't sign his informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noël CANO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Dorothée BAZIN KARA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier DUCLOUX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Elizabeth HENG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fitsum GUEBREEGZIABHE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis FOUQUE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe MARIAT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Atman HADDJELMRABET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier AGUILERA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric LARUELLE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles CHAZOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdallah GUERRAOUI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Myriam ISNARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Prisca MUTINELLI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène DE PRENEUF</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François MAURICE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro PALACIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel TETA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie ESSIG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Physical exercises</keyword>
  <keyword>Oral nutritional supplementation</keyword>
  <keyword>Multimodal</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Protein-Energy Wasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

